Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 11:44 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2497–2520 of 8,279 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Age Clear all

Conditions: Hematogenously Acquired Staphylococcus Aureus Osteomyelitis, Bone Infection, Osteomyelitis
Interventions: Ceftaroline Fosamil; Drug
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 1 Year to 17 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Prematurity, Respiratory Distress Syndrome,Hypoxemia
Interventions: Inhaled nitric oxide, Placebo; Drug
Lead sponsor: University of Chicago; Other
Eligibility: 4 Years to 6 Years
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Amblyopia
Interventions: Curesight dichoptic videos; Device
Lead sponsor: Retina Foundation of the Southwest; Other
Eligibility: 8 Years to 12 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: RLS
Interventions: HORIZANT 300 mg, HORIZANT 600 mg, Placebo; Drug
Lead sponsor: XenoPort, Inc.; Industry
Eligibility: 13 Years to 17 Years
Enrollment: 132 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2023
U.S. locations: 12
States / cities: Redwood City, California • Gulf Breeze, Florida • Winter Park, Florida + 9 more

Conditions: Pancreas Cancer, Pancreas Cyst, Pancreatic Ductal Adenocarcinoma, Genetic Predisposition
Interventions: Not listed
Lead sponsor: Arbor Research Collaborative for Health; Other
Eligibility: 18 Years to 90 Years
Enrollment: 20,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2030
U.S. locations: 46
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Burbank, California + 39 more

Conditions: Colorectal Cancer, Advanced Adenocarcinoma, Serrated Polyp
Interventions: ColoSense; Diagnostic Test
Lead sponsor: Geneoscopy, Inc.; Industry
Eligibility: 45 Years and older
Enrollment: 14,263 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2024
U.S. locations: 2
States / cities: St Louis, Missouri • Austin, Texas

Conditions: Glioblastoma, Cancer of Brain, Glioblastoma Multiforme, Brain Tumor
Interventions: Tumor Treating Fields, Temozolomide, Radiation Therapy; Device · Drug · Radiation
Lead sponsor: Providence Health & Services; Other
Eligibility: 22 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 2
States / cities: San Francisco, California • Portland, Oregon

Conditions: Chlamydia Trachomatis Infection, Gonorrhea
Interventions: Ct/GC screening; Other
Lead sponsor: Tulane University; Other
Eligibility: 15 Years to 26 Years · Male only
Enrollment: 1,907 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: New Orleans, Louisiana

Conditions: Macular Degeneration
Interventions: Lutein; Drug
Lead sponsor: National Eye Institute (NEI); NIH
Eligibility: Not listed
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2003
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Laxity; Skin
Interventions: On GLP1 plus HRT, On GLP1 Only; Drug
Lead sponsor: Goldman, Butterwick, Fitzpatrick and Groff; Other
Eligibility: 45 Years to 65 Years · Female only
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: San Diego, California

Conditions: Perinatal Hypoxia, Dopamine, Neurobehavioral Manifestations
Interventions: Magnetic Resonance Imaging, Cognitive Performance Testing; Other
Lead sponsor: Case Western Reserve University; Other
Eligibility: 8 Years to 15 Years
Enrollment: 21 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Metastatic Melanoma
Interventions: Nivolumab, Pembrolizumab, Dabrafenib+Trametinib, Ipilimumab+Nivolumab, Vemurafenib+Cobimetinib, Encorafenib+Binimetinib; Drug · Combination Product
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 1,975 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: East Hanover, New Jersey

Conditions: Brain Age
Interventions: DREEM EEG Device, SleepImage Ring; Device
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 108 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Fluid Retention, Sodium Retention, Heat Stress, Dehydration (Physiology), Renal Injury, Electrolyte and Fluid Balance Conditions
Interventions: PR Lotion - AMP Human Performance, Placebo Lotion, AminoVital - Rapid Recovery, Placebo Supplement; Other
Lead sponsor: University of Connecticut; Other
Eligibility: 18 Years to 45 Years · Male only
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Storrs, Connecticut

Conditions: Fatigue, Aging
Interventions: Placebo sildenafil, Sildenafil; Drug
Lead sponsor: The University of Texas Medical Branch, Galveston; Other
Eligibility: 20 Years to 80 Years · Male only
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Galveston, Texas

Conditions: Recurrent Pediatric ALL, Relapsed Pediatric ALL, Acute Lymphoblastic Leukemia, Refractory Pediatric ALL
Interventions: ABT-751, Dexamethasone, PEG-asparaginase, Doxorubicin, Cytarabine, Methotrexate, Cyclophosphamide, 6-thioguanine; Drug
Lead sponsor: Therapeutic Advances in Childhood Leukemia Consortium; Other
Eligibility: Up to 21 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 5
States / cities: Los Angeles, California • Palo Alto, California • San Francisco, California + 2 more

Conditions: Meningococcal Disease, Infections, Meningococcal
Interventions: Meningococcal quadrivalent CRM-197 conjugate vaccine; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 2 Months to 23 Months
Enrollment: 144 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Pasadena, California

Conditions: Wet Macular Degeneration
Interventions: KSI-301, Aflibercept, Sham Procedure; Drug · Other
Lead sponsor: Kodiak Sciences Inc; Industry
Eligibility: 50 Years and older
Enrollment: 559 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 59
States / cities: Phoenix, Arizona • Springdale, Arkansas • Bakersfield, California + 53 more

Conditions: Corneal Endothelial Cell Loss
Interventions: Topcon Specular Microscope SP-1P, Konan Specular Microscope CELLCHEK XL; Device
Lead sponsor: Topcon Medical Systems, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015
U.S. locations: 1
States / cities: Andover, Massachusetts

Conditions: Mucopolysaccharidosis Type IIIB, MPS IIIB (Sanfilippo B Syndrome)
Interventions: Tralesinidase alfa (TA); Drug
Lead sponsor: Spruce Biosciences; Industry
Eligibility: 12 Months and older
U.S. locations: 1
States / cities: Oakland, California

Conditions: Attention Deficit Hyperactivity Disorder
Interventions: HLD200 methylphenidate hydrochloride capsules, Placebo HLD200 capsules; Drug
Lead sponsor: Ironshore Pharmaceuticals and Development, Inc; Other
Eligibility: 4 Years to 5 Years
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 13
States / cities: Dothan, Alabama • Anaheim, California • Jacksonville, Florida + 10 more

Conditions: Generalized Anxiety Disorder, Sleep Disturbances
Interventions: Not listed
Lead sponsor: Children's National Research Institute; Other
Eligibility: 7 Years to 11 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2009
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Geographic Atrophy of the Macula, Macular Degeneration
Interventions: AVD-104, Avacincaptad; Drug
Lead sponsor: Aviceda Therapeutics, Inc.; Industry
Eligibility: 55 Years to 90 Years
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 56
States / cities: Gilbert, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 50 more

Conditions: Systemic Lupus Erythematosus
Interventions: Peripheral lab draws; Other
Lead sponsor: The Center for Rheumatic Disease, Allergy, & Immunology; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 75 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2013
U.S. locations: 1
States / cities: Kansas City, Missouri

Search by objective public record fields.

Ceftaroline for Treatment of Hematogenously Acquired Staphylococcus Aureus Osteomyelitis in Children

Follow-up at School-age of Children Who Participated in the Efficacy Study of Nitric Oxide for Premature Infants

Amblyopia Treatment for Children Aged 8 to 12 Years

An Efficacy and Safety Evaluation of HORIZANT in Adolescents With Moderate-to-Severe Primary RLS

Pancreatic Cancer Early Detection Consortium

Colorectal Cancer and Pre-Cancerous Adenoma Non-Invasive Detection Test Study

Tumor Treating Fields With Chemoradiation in Newly Diagnosed GBM

Check it: A New Approach to Controlling Chlamydia Transmission in Young People

Lutein for Age-Related Macular Degeneration

Evaluate the Safety and Efficacy of AGE Serum in Post-menopausal Patients on Hormone Replacement Therapy Taking Glucagon-like Peptide-1 Agonist

Measuring Brain Activity of School Age Children

Treatment Patterns and Outcomes of Targeted Therapy and Immunotherapy Among BRAF-Positive Melanoma Patients Treated in the Adjuvant Setting and Among BRAF-Positive Metastatic Melanoma Patients With Low Tumor Burden

Brain Age and Sleep Architecture in Meditators

The Effect of AMP Human Sodium Bicarbonate Lotion on Dehydrated Heat Stress

Role of Skeletal Muscle Nitric Oxide Production in Age-related Fatigue and Fatigability

ABT-751 With Chemotherapy for Relapsed Pediatric ALL

Meningococcal Quadrivalent CRM-197 Conjugate Vaccine Infant Study

A Study to Evaluate the Efficacy and Safety of KSI-301, an Anti-VEGF Antibody Biopolymer Conjugate, Versus Aflibercept in Patients With Neovascular (Wet) Age-Related Macular Degeneration.

Second Comparative Study of Specular Microscopes for Endothelial and Corneal Cell Measurements

Early Access Treatment With Tralesinidase Alfa in Mucopolysaccharidosis Type IIIB (Sanfilippo Syndrome Type B)

Efficacy, Safety & Pharmacokinetic (PK) Study of HLD200 in Children Aged 4-5 Years With ADHD

Mechanisms of Sleep Disturbance in Children With Generalized Anxiety Disorder (GAD)

A Multiple Dose Study of AVD-104 for Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)

Estrogen and Gender Biased Autoimmunity